BAT-4406F is under clinical development by Bio-Thera Solutions and currently in Phase I for Autoimmune Disorders. According to GlobalData, Phase I drugs for Autoimmune Disorders have a 73% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BAT-4406F’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BAT-4406F overview
BAT-4406F is under development for the treatment of neuromyelitis optica spectrum and autoimmune diseases. It is administered through intravenous route. The drug candidate is a anti-CD20 monoclonal antibody, it has an enhanced ADCC (antibody dependent cell-mediated cytotoxicity) effect. It acts by targeting cells expressing B lymphocyte antigen CD20.
It was also under development for treatment of cancer.
Bio-Thera Solutions overview
Bio-Thera Solutions (Bio-Thera) is a biopharmaceutical company that specializes in researching and developing novel therapeutics. It primarily focuses on the treatment of cancer, autoimmune, cardiovascular and eye diseases, and other severe unmet medical needs. The company offers products that include qletli, pobevcy, tofidence, and betagrin. Its pipeline products include humanized monoclonal antibodies and peptide drugs such as BAT8001, BAT8003, BAT1306, BAT2094, and BAT4306F. Bio-Thera’s products are used in the treatment of various diseases, with applications in the medical and healthcare industries. The company also develops biosimilars for existing, branded biologics to treat a range of cancer and autoimmune diseases. It operates in China and the US. Bio-Thera is headquartered in Guangzhou, Guangdong, China.
For a complete picture of BAT-4406F’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
